Working… Menu

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) (GMMG-BIRMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02834364
Recruitment Status : Active, not recruiting
First Posted : July 15, 2016
Last Update Posted : May 4, 2021
Array BioPharma
German Cancer Research Center
Coordinating Centre for Clinical Trials Heidelberg
University Hospital Heidelberg
Information provided by (Responsible Party):
Marc Raab, University of Heidelberg Medical Center

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : December 2021